Abstract
[No abstract]
| Original language | English |
|---|---|
| Pages (from-to) | 1043-1046 |
| Number of pages | 4 |
| Journal | Expert Review of Vaccines |
| Volume | 20 |
| Issue number | 9 |
| Early online date | 5 Jul 2021 |
| DOIs | |
| Publication status | Published - 19 Jul 2021 |
Bibliographical note
Funding Information:AJ Pollard is a member of the UK Dept. Health and Social Care’s (DHSC) Joint Committee on Vaccination & Immunisation (JCVI), but does not participate in policy decisions on COVID19 vaccine. He is a member of the WHO’s SAGE. The views expressed in this article do not necessarily represent the views of DHSC, JCVI, or WHO. AJ Pollard is chief investigator on clinical trials of Oxford University’s COVID19 vaccine funded by NIHR. Oxford University has entered a joint COVID19 vaccine development partnership with Astra Zeneca. A Finn is a member of the Joint Committee on Vaccination and Immunisation and Chair of the WHO European Technical Advisory Group of Experts (ETAGE) on Immunisation. He is an investigator and/or provides consultative advice on clinical trials and studies of COVID-19 vaccines produced by AstraZeneca, Janssen, Valneva, Pfizer and Sanofi and of other vaccines from these and other manufacturers including GSK, VPI, Takeda and Bionet Asia. He receives no personal remuneration or benefits for any of this work. G Li is a clinical research fellow at the University of Oxford. Oxford University has entered a joint COVID19 vaccine development partnership with Astra Zeneca.
Structured keywords
- Covid19
Keywords
- pediatric
- COVID-19
- PIMS-TS